DarioHealth Corp. (DRIO)

$3.95

+0.04 (+1.02%)
Rating:
Recommendation:
Neutral
Symbol DRIO
Price $3.95
Beta 1.348
Volume Avg. 0.16M
Market Cap 102.194M
Shares () -
52 Week Range 3.53-7.692
1y Target Est -
DCF Unlevered DRIO DCF ->
DCF Levered DRIO LDCF ->
ROE 47.85% Strong Buy
ROA 38.42% Strong Buy
Operating Margin -
Debt / Equity 48.99% Neutral
P/E -1.54 Sell
P/B 1.17 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest DRIO news


Mr. Erez Raphael
Healthcare
Diagnostics & Research
NASDAQ Capital Market

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.